Drugs / bacillus Calmette-Guerin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06186414 | Jan 2024 → Jan 2027 expected | non-invasive bladder urothelial carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bacillus Calmette-Guerin | “This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus...” NCT06186414 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06186414 ↗ |
| Route | Other | “BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically.” NCT06186414 ↗ |